Serum OPG/TRAIL ratio predicts the presence of cardiovascular disease in people with type 2 diabetes mellitus

H Forde; C Davenport; K D Rochfort; R G Wallace; E Durkan; A Agha; C J Thompson; W T Tormey; D J O'Gorman; P M Cummins; D Smith

doi:10.1016/j.diabres.2022.109936

Serum OPG/TRAIL ratio predicts the presence of cardiovascular disease in people with type 2 diabetes mellitus

Diabetes Res Clin Pract. 2022 Jul:189:109936. doi: 10.1016/j.diabres.2022.109936. Epub 2022 Jun 2.

Authors

H Forde¹, C Davenport², K D Rochfort³, R G Wallace⁴, E Durkan⁵, A Agha⁶, C J Thompson⁶, W T Tormey⁷, D J O'Gorman⁸, P M Cummins⁴, D Smith⁶

Affiliations

¹ Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont, Dublin 9, Ireland; School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. Electronic address: hannahforde@gmail.com.
² Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont, Dublin 9, Ireland; School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
³ School of Nursing, Psychotherapy, and Community Health, Dublin City University, Glasnevin, Dublin 9, Ireland.
⁴ School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
⁵ School of Health and Human Performance, Dublin City University, Glasnevin, Dublin 9, Ireland.
⁶ Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont, Dublin 9, Ireland.
⁷ Department of Chemical Pathology, Beaumont Hospital, Beaumont, Dublin 9, Ireland.
⁸ School of Health and Human Performance, Dublin City University, Glasnevin, Dublin 9, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

PMID: 35662613
DOI: 10.1016/j.diabres.2022.109936

Abstract

Aims: Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM). Epidemiological studies suggest serum Osteoprotegrin (OPG)/Tumour-necrosis-factor-related-apoptosis-inducing- ligand (TRAIL) ratio may be a useful marker of cardiovascular risk. This study aimed to compare serum levels of TRAIL, OPG and OPG/TRAIL ratio in people with T2DM, with and without a history of CVD, and controls; and to determine which of these indices, if any, predict cardiovascular risk.

Methods: In this single centre observational study of 133 participants, people with T2DM, with and without a history of a cardiovascular event in the last 5 years, were recruited along with a control cohort without T2DM or CVD. Demographic information and anthropometric measurements were recorded. Blood samples were taken and OPG and TRAIL were measured using ELISA.

Results: People with T2DM and CVD had higher OPG/TRAIL ratios compared to controls or those with a new diagnosis of T2DM. After adjustment for potential confounding factors, OPG/TRAIL ratio was significantly associated with the presence of CVD in people with T2DM and an OPG/TRAIL ratio cut-off > 38.6 predicted the presence of CVD in this cohort with a sensitivity of 80% and specificity of 82%.

Conclusion: This study suggests that OPG/TRAIL ratio may have a role as a biomarker of CVD in people with T2DM.

Keywords: Biomarker; Cardiovascular disease; Osteoprotegrin; Tumour-necrosis-factor-related apoptosis-inducing-ligand.

Publication types

Observational Study

MeSH terms

Biomarkers
Cardiovascular Diseases* / diagnosis
Cardiovascular Diseases* / etiology
Diabetes Mellitus, Type 2* / complications
Humans
Osteoprotegerin
TNF-Related Apoptosis-Inducing Ligand

Substances

Biomarkers
Osteoprotegerin
TNF-Related Apoptosis-Inducing Ligand